Gilead Sciences, Galapagos enter into R&D collaboration

Gilead Sciences, Galapagos enter into R&D collaboration

10:46 AM, 15th July 2019
Gilead Sciences, Galapagos logo

FOSTER CITY, US. & MECHELEN, BELGIUM: Gilead Sciences Inc and Galapagos NV have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.

The collaboration will allow for closer scientific partnership between the companies. Gilead will have access to Galapagos’ established research base, which includes more than 500 scientists, and to Galapagos’ unique platform, which utilizes disease-related, human primary cell-based assays to discover and verify novel drug targets. Gilead will also nominate two individuals to Galapagos’ Board of Directors following the closing of the transaction.

As part of the collaboration, Gilead gains rights to GLPG1690, Galapagos’ Phase 3 candidate for idiopathic pulmonary fibrosis. Gilead also receives option rights for GLPG1972, a Phase 2b candidate for osteoarthritis, in the United States. Both GLPG1690 and GLPG1972 are first-in-class compounds and could offer important mid- and late-stage pipeline opportunities for Gilead. In addition, Gilead receives option rights on all of Galapagos’ other current and future clinical programs outside of Europe.

In addition, Gilead and Galapagos have agreed to amend certain terms in the agreement governing filgotinib, the candidate being advanced for rheumatoid arthritis and other inflammatory diseases to provide a broader commercialization role for Galapagos in Europe.

Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib, the experimental compound being advanced for rheumatoid arthritis and other inflammatory diseases. The companies have recently completed the comprehensive Phase 3 FINCH program in rheumatoid arthritis and plan to seek regulatory approval for the medicine in the US and Europe before the end of the year.

Under the amended agreement, Galapagos will have greater involvement in filgotinib’s global strategy and participate more broadly in the commercialization of the product in Europe, providing the opportunity to build a commercial presence on an accelerated timeline.

 “We are excited to enter into this unique agreement, which will generate both long-term strategic value and mutual, immediate benefits. We chose to partner with Galapagos because of its pioneering target and drug discovery platform, proven scientific capabilities and outstanding team,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “Gilead also gains exclusive access to all current and future compounds in Galapagos’ rich pipeline while Galapagos is able to expand its research activities and build commercial infrastructure. The collaboration reflects Gilead’s intent to grow our innovation network through diverse and creative partnerships.”

 “What a fantastic moment in our 20th anniversary year to sign this landmark deal with our great partner Gilead,” said Onno van de Stolpe, Chief Executive Officer of Galapagos. “Galapagos has been highly effective at target identification and drug discovery, progressing novel molecules from research into the clinic. We will benefit greatly from Gilead’s expertise and infrastructure and believe this collaboration will provide an accelerated path to advance our pipeline. This agreement is about maximizing innovation based on developing new mode of action medicines. With the capital provided by Gilead, we aim to progress innovation to patients.”

Barclays, Centerview Partners and Lazard are acting as financial advisors to Gilead. Moelis & Co. and Morgan Stanley are acting as financial advisors to Galapagos. Skadden, Arps, Slate, Meagher & Flom, Covington & Burling LLP and Eubelius are serving as legal counsel to Gilead and Baker McKenzie and Linklaters are serving as legal counsel to Galapagos.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Nippon Shokubai breaks ground on $200 mn acrylic acid plant

TOKYO, JAPAN: Nippon Shokubai Co Ltd’s subsidiary PT. Nippon Shokubai Indonesia held a ground-breaking ceremony for the new acrylic acid plant i ...

Read more
Teva Pharma purchases facilities in Pennsylvania for R&D campus

PARSIPPANY, US: Teva Pharmaceuticals USA Inc has completed the purchase of three buildings on Brandywine Parkway in West Chester, Pennsylvania. Toget ...

Read more
McDermott starts world's largest catalytic dehydrogenation plant

HOUSTON, US: McDermott International Inc announced the recent successful startup of the world's largest catalytic dehydrogenation plant, which is loca ...

Read more
AGM achieves progress in development of anti-corrosion coatings

LONDON, UK: Applied Graphene Materials, the producer of specialty graphene materials has achieved significant technological progress (patent pending) ...

Read more
Assam Gas, Oil India & GAIL sign pact for setting up new CGD company

GUWAHATI, INDIA: Assam Gas Company Ltd (AGCL), Oil India Limited (OIL) and GAIL Gas Ltd has signed a joint venture agreement for incorporating a new c ...

Read more
Indian researchers develop sustainable paints using litchi extracts

PUNJAB, INDIA: Increasing use of synthetic paints has over the years become a cause for worry with the World Health Organization (WHO) reporting a 20- ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X